Quick Answer
Protara Therapeutics, Inc. reported Stockholders Equity of $196.41 million for fiscal year 2025.
Protara Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $196.41M | +17.5% |
| 2024 | $167.13M | +144.6% |
| 2023 | $68.32M | -33.1% |
| 2022 | $102.08M | -37.0% |
| 2021 | $161.91M | -18.7% |
| 2020 | $199.24M | +9462.9% |
| 2019 | -$2.13M | -144.5% |
| 2018 | $4.78M | -86.2% |
| 2017 | $34.74M | -9.6% |
| 2016 | $38.44M | -39.4% |
| 2015 | $63.41M | -23.1% |
| 2014 | $82.46M | +182.0% |
| 2013 | -$100.51M | -16.0% |
| 2012 | -$86.66M | -19.3% |
| 2011 | -$72.66M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $132.29M | +61.7% | -8.4% |
| June 30, 2025 | $144.42M | +56.9% | -8.9% |
| March 31, 2025 | $158.48M | +171.3% | -5.2% |
| December 31, 2024 | $167.13M | +144.6% | +104.3% |
| September 30, 2024 | $81.79M | +6.3% | -11.1% |
| June 30, 2024 | $92.05M | +8.0% | +57.6% |
| March 31, 2024 | $58.41M | -38.4% | -14.5% |
| December 31, 2023 | $68.32M | -33.1% | -11.2% |
- Protara Therapeutics, Inc. showed an increase of +17.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Protara Therapeutics, Inc.’s stockholders equity has grown by 370.3% (from -$72.66 million to $196.41 million).
- The most recent figure is from Protara Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: